Drug Profile
Paclitaxel - CLL PHARMA
Alternative Names: SYN 2001; Syn2001Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Synt:em
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Brain cancer
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Brain-cancer in France
- 01 Jun 2016 Chemical structure information added
- 31 May 2016 Phase-I development is ongoing in Brain cancer in France (CLL PHARMA pipeline, May 2016)